Drug Profile


Alternative Names: Hepatitis C virus ribozyme; LY 466700

Latest Information Update: 08 Jan 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sirna Therapeutics
  • Class Antivirals; Ribozymes
  • Mechanism of Action RNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 30 Apr 2002 Suspended - Phase-II for Hepatitis C in USA (unspecified route)
  • 08 Oct 2001 Phase-II clinical trials for Hepatitis C in USA (Unknown route)
  • 15 Nov 2000 A study has been added to the adverse events and Viral Infections therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top